Literature DB >> 30500264

Demystifying biosimilars: development, regulation and clinical use.

Hope S Rugo1, Robert M Rifkin2, Paul Declerck3, Angel H Bair4, Geraint Morgan4.   

Abstract

Biologics are an integral component in the treatment of various diseases. However, limited patient access to these medicines remains a significant global challenge, prompting development of safe and effective biosimilars. A biosimilar is 'highly similar to a reference (originator) product, for which there are no clinically meaningful differences between the two products in terms of safety, purity and potency'. Biosimilars have the potential to offer possible benefits, including lower treatment costs, thereby increasing patient access and clinical use, which may lead to better overall outcomes. Improved understanding of biosimilars may enhance confidence and trust in these agents. As increasing numbers of biosimilars achieve regulatory approval, this overview aims to address enduring knowledge gaps regarding the development and use of biosimilars.

Entities:  

Keywords:  biosimilar; development; extrapolation; interchangeability; myths; regulatory approval

Mesh:

Substances:

Year:  2018        PMID: 30500264     DOI: 10.2217/fon-2018-0680

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  5 in total

1.  Proteomics for cancer drug design.

Authors:  Amanda Haymond; Justin B Davis; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2019-08-04       Impact factor: 3.940

2.  Practical Issues Concerning the Approval and Use of Biosimilar Drugs for the Treatment of Multiple Sclerosis in Latin America.

Authors:  Judith Steinberg; Yara D Fragoso; Juan Carlos Duran Quiroz; Juan Raul García; Caroline Guerra; Virginia Rodriguez; Claudia Carcamo Rodriguez; Ethel Ciampi; Edgar Correa-Diaz; Miguel Macías; Nelson Novarro; Darwin Vizcarra; Carlos Oehninger Gatti; Geraldine Orozco; Adriana Carrá
Journal:  Neurol Ther       Date:  2019-05-24

Review 3.  Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!

Authors:  Binita Dutta; Isabelle Huys; Arnold G Vulto; Steven Simoens
Journal:  BioDrugs       Date:  2020-04       Impact factor: 5.807

Review 4.  Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States.

Authors:  Emily M Miller; Lee S Schwartzberg
Journal:  Ther Adv Med Oncol       Date:  2019-11-14       Impact factor: 8.168

Review 5.  Current and future roles of biosimilars in oncology practice.

Authors:  Sofia Konstantinidou; Angeliki Papaspiliou; Eleni Kokkotou
Journal:  Oncol Lett       Date:  2019-11-15       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.